National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning 530021, Guangxi, China.
Corresponding author.
Discov Med. 2020 May-Jun;29(158):159-167.
Cancer is a major cause of disease-related deaths worldwide, and early diagnosis involving detecting biomarkers of tumors can improve the cure rate and prognosis of patients. Biomarkers are signature proteins that can distinguish diseased cells from healthy cells, facilitating the diagnosis and treatment of diseases, especially cancer. Aptamers are single-stranded oligonucleotides that can recognize target proteins with high affinity and specificity. The development of biomarkers identified by aptamers has experienced extensive progress in current applications. The combinatorial strategy of cell-SELEX technology and proteomics analysis makes targeted protein identification more cost-effective and efficient and improves the success rate of discovery of multiple biomarkers simultaneously. In this methodology, biomarkers are identified via a series of operations such as screening of aptamers, separation, extraction, and analysis of target proteins, which has brought about the discovery of a number of new biomarkers of cancer. This review summarizes the current strategies, challenges, and potential applications for biomarker discovery using aptamers engendered by cell-SELEX.
癌症是全球疾病相关死亡的主要原因，通过检测肿瘤的生物标志物进行早期诊断可以提高患者的治愈率和预后。生物标志物是能够区分病变细胞和健康细胞的特征蛋白，有助于疾病的诊断和治疗，尤其是癌症。适体是能够与靶蛋白高亲和力和特异性结合的单链寡核苷酸。目前应用中，基于适体的生物标志物的开发已经取得了广泛的进展。细胞 SELEX 技术与蛋白质组学分析的组合策略使得靶向蛋白的鉴定更具成本效益和效率，同时提高了同时发现多个生物标志物的成功率。在这种方法中，通过一系列操作来识别生物标志物，如适体的筛选、靶蛋白的分离、提取和分析，这带来了许多新的癌症生物标志物的发现。本综述总结了基于细胞 SELEX 的适体生物标志物发现的当前策略、挑战和潜在应用。
